Results 91 to 100 of about 5,421 (159)

Clinical Characteristics and in vitro Activities of Sulbactam-durlobactam and Cefiderocol against Carbapenem-resistant Acinetobacter baumannii Infections in Chinese Children: A Multicenter Study

Objective To systematically characterize the carbapenem-resistant Acinetobacter baumannii (CRAB) infections in children and to identify risk factors associated with 28-day mortality. We evaluated the
Wei Xie, Zhenlong Wang, Chunmei Jing, jingyi Dong, lijun zhang, Gaihuan Zheng, Zhongzheng Xiong, Cai Wang, Yupei Xiang   +8 more
core   +1 more source

Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii

Current Research in Microbial Sciences
Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a formidable clinical challenge, driven by limited therapeutic options and multifaceted resistance mechanisms.
Chunhong Yang, Jing Li, Xiao Luo, Zhangyong Song, Jinping Zhang   +4 more
doaj   +1 more source

Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs

Emerging Infectious Diseases
The US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking.
Mayurika Ghosh, Dmitri Iarikov, Xiaojing (Karen) Qi, Daniel Rubin, Simone Shurland, Avery Goodwin, Xiaohui Wei, Dakshina Chilukuri, Owen McMaster, Terry Miller, Peter Kim, Adam Sherwat   +11 more
doaj   +1 more source

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii

Frontiers in Cellular and Infection Microbiology
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment ...
Siqin Zhang, Lingfang Di, Yan Qi, Xiang Qian, Siwei Wang   +4 more
doaj   +1 more source

New Antibiotics for Lower Respiratory Tract Infections

Microbiology Research
Respiratory tract infections are frequently encountered in clinical practice. The growing incidence of antimicrobial resistance among the causative pathogens exerts sustained pressure on the existing therapeutic options.
Despoina Papageorgiou, Maria Gavatha, Dimitrios Efthymiou, Eleni Polyzou, Aristotelis Tsiakalos, Karolina Akinosoglou   +5 more
doaj   +1 more source

Systematic and quantitative analyses of hollow fiber model of Mycobacterium abscessus lung disease studies and new dosing recommendations

Microbiology Spectrum
Guideline-based combination therapy achieves sputum culture conversion rates in 23%–34% of patients with Mycobacterium abscessus-complex lung disease. Thus, new therapies are needed.
Shashikant Srivastava, Tawanda Gumbo
doaj   +1 more source

P-1215. In vitro activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates from wound and urinary tract sources: ACNBio Study 2023-2025 [PDF]

Open Forum Infect Dis
Background Acinetobacter baumannii most often causes nosocomial bacteremia and pneumonia. However, A. baumannii is becoming an important cause of a broader range of infections including skin and soft tissue infection (SSTI) and urinary tract infections ...
Kirn, Thomas, Chavez, Violeta, Westblade, Lars, Mutnal, Manohar B, Potula, Raghava, Daniels, Anne R, Pierce, Virginia M, Beck, Eric T, Narayanan, Navaneeth, Simner, Patricia J, Cyr, Elizabeth, Fisher, Mark, Argotsinger, Jill, Dumm, Rebekah, Gialanella, Philip, Kufel, Wesley D, Chamberland, Robin R, Marino, Jamie, Huse, Holly, Abbo, Lilian M, Hamilton-Seth, Robert, Riddell, Scott W, Jenkins, Timothy C, Harrington, Amanda, Asempa, Tomefa E, Hankins, Julia, Tibbetts, Robert, Vu, Christine A, Tekle, Tsigereda, Humphries, Romney, Clark, Andrew E, Mochon, Brian, Nicolau, David P, Martinez, Octavio, Hand, Jonathan, Liesman, Rachel   +35 more
europepmc   +2 more sources

The Role of Combination Antibiotic Therapy in Combatting Drug-Resistant Acinetobacter baumannii Infections: A Systematic Review of Randomised Control Trials

Antibiotics
Background: Acinetobacter baumannii is a major global health threat due to its rapid acquisition of multidrug resistance, particularly to carbapenems.
Anteneh Assefa Gezmu, Abel Workalemahu Tesfaye, Anthony R. M. Coates   +2 more
doaj   +1 more source

P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant Acinetobacter baumannii in India: an institutional experience

JAC-Antimicrobial Resistance
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) is a WHO designated ‘critical priority’ pathogen because of its high capacity for multidrug resistance and association with mortality rates approaching 50% in severe hospital-acquired infections.
Nizam Ahmed, M, Singh, Parul, Kirti, Madhavi, Das, Bharat Chandra, Tluanpuii, Vanlal, Kumar, Subodh, Sagar, Sushma, Soni, Kapil Dev, Aggarwal, Richa, Bindra, Ashish, Goyal, Keshav, Singh, Gyanendra Pal, Sokhal, Navdeep, Farooque, Kamran, Mathur, Purva   +14 more
openaire   +1 more source

Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii

npj Antimicrobials and Resistance
The multiply antibiotic-resistant lineage 1 of Acinetobacter baumannii global clone 1 (GC1) emerged in the 1970s, and subsequently more extensively resistant sublineages have emerged.
Christopher J. Harmer, Ting L. Luo, Francois Lebreton, Patrick T. McGann, Ruth M. Hall   +4 more
doaj   +1 more source